Global Oncology Biomarker 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR082404735

Publication Date:

August 8, 2024

Pages:

110

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Oncology Biomarker market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
A biomarker is referred to as a traceable biomolecule, whose presence found in body fluids such as blood, serum, urine, and tumor fluid that indicates disease or an underlying condition such as cancer.
This report includes an overview of the development of the Oncology Biomarker industry chain, the market status of Diagnostics (Lung Cancer, Breast Cancer), Drug Discovery And Development (Lung Cancer, Breast Cancer), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Oncology Biomarker.
Regionally, the report analyzes the Oncology Biomarker markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Oncology Biomarker market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Oncology Biomarker market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Oncology Biomarker industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Lung Cancer, Breast Cancer).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Oncology Biomarker market.
Regional Analysis: The report involves examining the Oncology Biomarker market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Oncology Biomarker market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Oncology Biomarker:
Company Analysis: Report covers individual Oncology Biomarker players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Oncology Biomarker This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Diagnostics, Drug Discovery And Development).
Technology Analysis: Report covers specific technologies relevant to Oncology Biomarker. It assesses the current state, advancements, and potential future developments in Oncology Biomarker areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Oncology Biomarker market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Oncology Biomarker market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others
麻豆原创 segment by Application
Diagnostics
Drug Discovery And Development
Prognostics
Risk Assessment
Others
麻豆原创 segment by players, this report covers
Abbott Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
F.Hoffmann-La Roche Ltd.
Genomic Health
GlaxoSmithKline plc
Novartis AG
Merck & Co.
Pfizer
Qiagen N.V.
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Oncology Biomarker product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oncology Biomarker, with revenue, gross margin and global market share of Oncology Biomarker from 2019 to 2024.
Chapter 3, the Oncology Biomarker competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Oncology Biomarker market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oncology Biomarker.
Chapter 13, to describe Oncology Biomarker research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope of Oncology Biomarker
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Oncology Biomarker by Type
1.3.1 Overview: Global Oncology Biomarker 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Oncology Biomarker Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Lung Cancer
1.3.4 Breast Cancer
1.3.5 Colorectal Cancer
1.3.6 Prostate Cancer
1.3.7 Stomach Cancer
1.3.8 Others
1.4 Global Oncology Biomarker 麻豆原创 by Application
1.4.1 Overview: Global Oncology Biomarker 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Diagnostics
1.4.3 Drug Discovery And Development
1.4.4 Prognostics
1.4.5 Risk Assessment
1.4.6 Others
1.5 Global Oncology Biomarker 麻豆原创 Size & Forecast
1.6 Global Oncology Biomarker 麻豆原创 Size and Forecast by Region
1.6.1 Global Oncology Biomarker 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Oncology Biomarker 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Oncology Biomarker 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Oncology Biomarker 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Oncology Biomarker 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Oncology Biomarker 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Oncology Biomarker 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business
2.1.3 Abbott Laboratories Oncology Biomarker Product and Solutions
2.1.4 Abbott Laboratories Oncology Biomarker Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Abbott Laboratories Recent Developments and Future Plans
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb Oncology Biomarker Product and Solutions
2.2.4 Bristol-Myers Squibb Oncology Biomarker Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.3 Eli Lilly and Company
2.3.1 Eli Lilly and Company Details
2.3.2 Eli Lilly and Company Major Business
2.3.3 Eli Lilly and Company Oncology Biomarker Product and Solutions
2.3.4 Eli Lilly and Company Oncology Biomarker Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Eli Lilly and Company Recent Developments and Future Plans
2.4 F.Hoffmann-La Roche Ltd.
2.4.1 F.Hoffmann-La Roche Ltd. Details
2.4.2 F.Hoffmann-La Roche Ltd. Major Business
2.4.3 F.Hoffmann-La Roche Ltd. Oncology Biomarker Product and Solutions
2.4.4 F.Hoffmann-La Roche Ltd. Oncology Biomarker Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 F.Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.5 Genomic Health
2.5.1 Genomic Health Details
2.5.2 Genomic Health Major Business
2.5.3 Genomic Health Oncology Biomarker Product and Solutions
2.5.4 Genomic Health Oncology Biomarker Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Genomic Health Recent Developments and Future Plans
2.6 GlaxoSmithKline plc
2.6.1 GlaxoSmithKline plc Details
2.6.2 GlaxoSmithKline plc Major Business
2.6.3 GlaxoSmithKline plc Oncology Biomarker Product and Solutions
2.6.4 GlaxoSmithKline plc Oncology Biomarker Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 GlaxoSmithKline plc Recent Developments and Future Plans
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Oncology Biomarker Product and Solutions
2.7.4 Novartis AG Oncology Biomarker Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Novartis AG Recent Developments and Future Plans
2.8 Merck & Co.
2.8.1 Merck & Co. Details
2.8.2 Merck & Co. Major Business
2.8.3 Merck & Co. Oncology Biomarker Product and Solutions
2.8.4 Merck & Co. Oncology Biomarker Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Merck & Co. Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Oncology Biomarker Product and Solutions
2.9.4 Pfizer Oncology Biomarker Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 Qiagen N.V.
2.10.1 Qiagen N.V. Details
2.10.2 Qiagen N.V. Major Business
2.10.3 Qiagen N.V. Oncology Biomarker Product and Solutions
2.10.4 Qiagen N.V. Oncology Biomarker Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Qiagen N.V. Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Oncology Biomarker Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Oncology Biomarker by Company Revenue
3.2.2 Top 3 Oncology Biomarker Players 麻豆原创 Share in 2023
3.2.3 Top 6 Oncology Biomarker Players 麻豆原创 Share in 2023
3.3 Oncology Biomarker 麻豆原创: Overall Company Footprint Analysis
3.3.1 Oncology Biomarker 麻豆原创: Region Footprint
3.3.2 Oncology Biomarker 麻豆原创: Company Product Type Footprint
3.3.3 Oncology Biomarker 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Oncology Biomarker Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Oncology Biomarker 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Oncology Biomarker Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Oncology Biomarker 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Oncology Biomarker Consumption Value by Type (2019-2030)
6.2 North America Oncology Biomarker Consumption Value by Application (2019-2030)
6.3 North America Oncology Biomarker 麻豆原创 Size by Country
6.3.1 North America Oncology Biomarker Consumption Value by Country (2019-2030)
6.3.2 United States Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Oncology Biomarker Consumption Value by Type (2019-2030)
7.2 Europe Oncology Biomarker Consumption Value by Application (2019-2030)
7.3 Europe Oncology Biomarker 麻豆原创 Size by Country
7.3.1 Europe Oncology Biomarker Consumption Value by Country (2019-2030)
7.3.2 Germany Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Oncology Biomarker Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Oncology Biomarker Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Oncology Biomarker 麻豆原创 Size by Region
8.3.1 Asia-Pacific Oncology Biomarker Consumption Value by Region (2019-2030)
8.3.2 China Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Oncology Biomarker Consumption Value by Type (2019-2030)
9.2 South America Oncology Biomarker Consumption Value by Application (2019-2030)
9.3 South America Oncology Biomarker 麻豆原创 Size by Country
9.3.1 South America Oncology Biomarker Consumption Value by Country (2019-2030)
9.3.2 Brazil Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Oncology Biomarker Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Oncology Biomarker Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Oncology Biomarker 麻豆原创 Size by Country
10.3.1 Middle East & Africa Oncology Biomarker Consumption Value by Country (2019-2030)
10.3.2 Turkey Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Oncology Biomarker 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Oncology Biomarker 麻豆原创 Drivers
11.2 Oncology Biomarker 麻豆原创 Restraints
11.3 Oncology Biomarker Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Oncology Biomarker Industry Chain
12.2 Oncology Biomarker Upstream Analysis
12.3 Oncology Biomarker Midstream Analysis
12.4 Oncology Biomarker Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Abbott Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
F.Hoffmann-La Roche Ltd.
Genomic Health
GlaxoSmithKline plc
Novartis AG
Merck & Co.
Pfizer
Qiagen N.V.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.